Clinical Trials Logo

Daratumumab clinical trials

View clinical trials related to Daratumumab.

Filter by:
  • None
  • Page 1

NCT ID: NCT05835726 Recruiting - Multiple Myeloma Clinical Trials

Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.

DILEMMA
Start date: January 1, 2022
Phase:
Study type: Observational

Daratumumab is a human first-in-class monoclonal antibody that targets a cluster of differentiation (CD) 38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells, showing significant activity in relapsed/refractory disease. More recently, it was demonstrated that the addition of daratumumab to pre-autologous hematopoietic stem cell transplant (ASCT) induction regimens in newly diagnosed multiple myeloma increased the rate of complete responses and disease-free survival. However, in consideration of the expression of CD38 antigen also by stem cells, daratumumab could exert effects on their mobilization, collection, and engraftment. The primary objective of this retrospective/prospective observational study is to investigate the impact of adding daratumumab to standard induction regimens (VTD:bortezomib-thalidomide and dexamethasone, VD: bortezomib and dexamethasone) on stem cell mobilization in patients with newly diagnosed multiple myeloma (NDMM) who are candidates for ASCT.

NCT ID: NCT04065308 Recruiting - Clinical trials for Multiple Myeloma in Relapse

Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma

Dara_DCEP
Start date: January 14, 2019
Phase: Phase 2
Study type: Interventional

This trial aimed to investigate the therapeutic efficacy of daratumumnab plus chemitherapy in multiple myeloma with plasmacytoma.